TABLE 2

Change from baseline in forced expiratory volume in 1 s (FEV1) and trough FEV1 at week 24

FF/UMEC/VI populationNon-ELLIPTA MITT populationFF/UMEC/VI versus non-ELLIPTA MITT
Patients910904
FEV1#
 Patients691675
 FEV1 mL1446 (1425–1467)1396 (1375–1418)50 (26–73); p<0.001
 FEV1 mL change from baseline77 (57–98)28 (6–49)
Trough FEV1
 Patients301292
 FEV1 mL1498 (1462–1534)1445 (1404–1486)53 (9–96); p=0.017
 FEV1 mL change from baseline100 (64–135)47 (6–88)

Data are presented as n or least-squares mean (95% CI), unless otherwise stated. FF: fluticasone furoate; UMEC: umeclidinium; VI: vilanterol; MITT: multiple-inhaler triple therapy. #: data include both trough and non-trough values; : patients with imputed FEV1, n=82 (FF/UMEC/VI), n=115 (non-ELLIPTA MITT). Trough FEV1 is defined as the FEV1 value recorded while patients have withheld COPD maintenance, short-acting β2-agonist and short-acting muscarinic receptor antagonist treatment. For COPD maintenance treatments taken once daily, FEV1 was considered as trough if the patient withheld the LABA and LAMA components of the maintenance treatment for ≥16 h. For COPD maintenance treatments taken twice daily, FEV1 was considered as trough if the patient withheld the LABA and LAMA components of the maintenance treatment for ≥8 h.